Skip to search formSkip to main contentSkip to account menu

cytarabine/gemtuzumab ozogamicin/mitoxantrone

Known as: ARA-C/CMA-676/DHAD 
National Institutes of Health

Related topics

Related topics

3 relations
CytarabineGemtuzumab ozogamicinMitoxantrone Hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis…
2018
2018
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We… 
2014
2014
Final Analysis of the ALFA 0701 Study
Aim: The first analysis of the ALFA-0701 study, testing the addition of gemtuzumab ozogamicin (GO) to standard treatment in de… 
2008
2008
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
BACKGROUND Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated… 
Review
2007
Review
2007
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
2007
2007
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience
We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of… 
2006
2006
Gemtuzumab ozogamicin‐induced sinusoidal obstructive syndrome treated with defibrotide: a case report
New treatments for relapse of acute myeloid leukaemia (AML), include gemtuzumab ozogamicin (GO), an anti‐CD33 monoclonal antibody… 
2005
2005
Two Patients with All -trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Treated Successfully with Gemtuzumab Ozogamicin as a Single Agent
Acute promyelocytic leukemia (APL) cells express a considerable level of CD33, which is the target of gemtuzumab ozogamicin (GO… 
Review
2004
Review
2004
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
BACKGROUND Gemtuzumab ozogamicin (GO) is approved for the treatment of older adults with acute myeloid leukemia in first relapse… 
2001
2001
Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . . 
Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . . 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)